Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARGOS THERAPEUTICS INCARGS · Entity 167312 | Director | January 19, 2017 | January 20, 2017 |
| Beyond Air, Inc.XAIR · Entity 8379 | Director | November 04, 2025 | November 07, 2025 |
| Disc Medicine, Inc.FSDC · Entity 2273 | Director | August 11, 2020 | August 12, 2020 |
| Horizon Therapeutics Public Ltd CoHZNP · Entity 109157 | EVP, Chief Business Officer | March 23, 2019 | March 25, 2019 |
| SANGAMO THERAPEUTICS, INCSGMO · Entity 7038 | Director | June 12, 2025 | June 16, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARGOS THERAPEUTICS INC
Report date January 19, 2017 · Filed January 20, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.85 · Expires 2027-01-18 | Direct | 9,500 |
Reported balance
After 2017-01-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-19 · Grant · Acquired 9,500 · Balance 9,500 |
Beyond Air, Inc.
Report date November 04, 2025 · Filed November 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.80 | Direct | 0 |
Reported balance
After 2025-11-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-04 · Disposition to issuer · Disposed 4,500 · Balance 0 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 | Direct | 4,500 |
Reported balance
After 2025-11-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-11-04 · Grant · Acquired 4,500 · Balance 4,500 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.80 | Direct | 0 |
Reported balance
After 2025-11-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-11-04 · Disposition to issuer · Disposed 2,000 · Balance 0 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 | Direct | 2,000 |
Reported balance
After 2025-11-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-11-04 · Grant · Acquired 2,000 · Balance 2,000 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.80 | Direct | 0 |
Reported balance
After 2025-11-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-11-04 · Disposition to issuer · Disposed 1,500 · Balance 0 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 | Direct | 1,500 |
Reported balance
After 2025-11-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-11-04 · Grant · Acquired 1,500 · Balance 1,500 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.80 | Direct | 0 |
Reported balance
After 2025-11-04 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-11-04 · Disposition to issuer · Disposed 1,250 · Balance 0 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 | Direct | 1,250 |
Reported balance
After 2025-11-04 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-11-04 · Grant · Acquired 1,250 · Balance 1,250 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.80 | Direct | 0 |
Reported balance
After 2025-11-04 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-11-04 · Disposition to issuer · Disposed 1,250 · Balance 0 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 | Direct | 1,250 |
Reported balance
After 2025-11-04 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-11-04 · Grant · Acquired 1,250 · Balance 1,250 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.80 | Direct | 0 |
Reported balance
After 2025-11-04 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2025-11-04 · Disposition to issuer · Disposed 50 · Balance 0 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 | Direct | 50 |
Reported balance
After 2025-11-04 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2025-11-04 · Grant · Acquired 50 · Balance 50 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.80 | Direct | 0 |
Reported balance
After 2025-11-04 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2025-11-04 · Disposition to issuer · Disposed 1,250 · Balance 0 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 | Direct | 1,250 |
Reported balance
After 2025-11-04 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2025-11-04 · Grant · Acquired 1,250 · Balance 1,250 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.89 | Direct | 0 |
Reported balance
After 2025-11-04 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2025-11-04 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 | Direct | 10,000 |
Reported balance
After 2025-11-04 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2025-11-04 · Grant · Acquired 10,000 · Balance 10,000 F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged.
F2: This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
Disc Medicine, Inc.
Report date August 11, 2020 · Filed August 12, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-08-11 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for stock splits, stock capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination or earlier at the option of the holder, on a one-for-one basis, subject to adjustment for stock splits, stock capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
Horizon Therapeutics Public Ltd Co
Report date March 23, 2019 · Filed March 25, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 17,267 |
Ending reported balance
After 2019-03-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-03-23 · Exercise / conversion · Acquired 31,000 · Balance 31,000 F1: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Row 2 · 2019-03-23 · Tax withholding · Disposed 13,733 · Balance 17,267 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-03-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-03-23 · Exercise / conversion · Disposed 31,000 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F3: On March 23, 2015, the reporting person was granted 124,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Robert F. Carey III Trust dated 4/24/2001 | 249,091 |
Reported balance
Holding disclosure · report date 2019-03-23 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 249,091 F2: Includes 40,311 shares previously reported as directly held by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
F2: Includes 40,311 shares previously reported as directly held by the Reporting Person.
F3: On March 23, 2015, the reporting person was granted 124,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
SANGAMO THERAPEUTICS, INC
Report date June 12, 2025 · Filed June 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 99,600 |
Reported balance
After 2025-06-12 transaction · row 1
1 source rowRow 1 · 2025-06-12 · Grant · Acquired 25,000 · Balance 99,600 F1: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2035-06-11 | Direct | 50,000 |
Reported balance
After 2025-06-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-12 · Grant · Acquired 50,000 · Balance 50,000 F2: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.
F2: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2019 Filed Jun 12, 2019 21:04 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-036434 · doc4.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) June 10, 2020 (the first anniversary of the date of grant) or (y) the day prior to the 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| June 03, 2019 Filed Nov 22, 2019 16:05 UTC | Beyond Air, Inc. XAIR · Entity 8379 | PurchaseCommon Stock | 19,418 | $5.15 | $100,002.70 |
DisclosureSEC source: 0001493152-19-018256 · ownership.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,418 F1 · price: Closing price of common stock on May 31, 2019. Read SEC document |
| March 23, 2019 Filed Mar 25, 2019 21:12 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units · Derivative | 31,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-021268 · doc4.xml · derivative · entry 4 Carey Robert · CIK 0001602064 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 31,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: On March 23, 2015, the reporting person was granted 124,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On March 23, 2015, the reporting person was granted 124,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| March 23, 2019 Filed Mar 25, 2019 21:12 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 13,733 | $26.84 | $368,593.72 |
DisclosureSEC source: 0001209191-19-021268 · doc4.xml · nonDerivative · entry 2 Carey Robert · CIK 0001602064 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,267 Read SEC document |
| March 23, 2019 Filed Mar 25, 2019 21:12 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 31,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-021268 · doc4.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 17:21 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 32,064 | $21.54 | $690,658.56 |
DisclosureSEC source: 0001209191-19-012695 · doc4.xml · nonDerivative · entry 2 Carey Robert · CIK 0001602064 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,311 Read SEC document |
| February 20, 2019 Filed Feb 22, 2019 17:21 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantOrdinary Shares | 72,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-012695 · doc4.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,375 F1 · kind: On January 5, 2018, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 20, 2019, the PSUs vested as to the number of shares reported above, upon the Issuer's determination that certain performance criteria had been met. F1 · shares: On January 5, 2018, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 20, 2019, the PSUs vested as to the number of shares reported above, upon the Issuer's determination that certain performance criteria had been met. Read SEC document |
| February 13, 2019 Filed Feb 22, 2019 16:30 UTC | Beyond Air, Inc. AITB · Entity 8379 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0001493152-19-002451 · ownership.xml · derivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common stock · 25,000 shares Expires 2022-12-31 F1 · derivative.exercise_date: The options will vest as to 25% of the shares on December 31, 2019 and on December 31 of each of the three ensuing years thereafter until vested in full (provided that the last vesting date shall occur on the date before the Options expire.) Read SEC document |
| January 05, 2019 Filed Jan 8, 2019 20:37 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units (RSU) · Derivative | 65,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-002934 · doc4.xml · derivative · entry 5 Carey Robert · CIK 0001602064 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,392 Underlying: Ordinary Shares · 65,695 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F4 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2018. F4 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2018. Read SEC document |
| January 05, 2019 Filed Jan 8, 2019 20:37 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 29,419 | $20.39 | $599,853.41 |
DisclosureSEC source: 0001209191-19-002934 · doc4.xml · nonDerivative · entry 2 Carey Robert · CIK 0001602064 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,276 Read SEC document |
| January 05, 2019 Filed Jan 8, 2019 20:37 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 65,695 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-002934 · doc4.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 20:37 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units (RSU) · Derivative | 53,948 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-002934 · doc4.xml · derivative · entry 4 Carey Robert · CIK 0001602064 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,948 Underlying: Ordinary Shares · 53,948 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2019. F3 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2019. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 00:24 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $15.65 | $0.00 |
DisclosureSEC source: 0001209191-18-037344 · doc4.xml · derivative · entry 2 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-10 F2 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 12 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 12-month period measured from the grant date. Read SEC document |
| June 11, 2018 Filed Jun 13, 2018 00:24 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-037344 · doc4.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F1 · shares: Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will fully vest on the earlier of (x) June 11, 2019 (the first anniversary of the date of grant) or (y) the day prior to the 2019 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| May 03, 2018 Filed May 7, 2018 20:24 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units (RSU) · Derivative | 197,087 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-028482 · doc4.xml · derivative · entry 1 Carey Robert · CIK 0001602064 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,087 Underlying: Ordinary Shares · 197,087 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F2 · date: The RSU's were approved by the Issuer's Compensation Committee on January 5, 2018, subject to shareholder approval of certain amendments to the Issuer's 2014 Equity Incentive Plan (the "Plan") under which the RSU's were granted. The Issuer's shareholders approved the amendments to the Plan on May 3, 2018. F3 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2018. F1 · derivative.expiration_date: Each RSU represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 17:29 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units · Derivative | 31,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-021781 · doc4.xml · derivative · entry 4 Carey Robert · CIK 0001602064 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,000 Underlying: Ordinary Shares · 31,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: On March 23, 2015, the reporting person was granted 124,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F2 · derivative.expiration_date: On March 23, 2015, the reporting person was granted 124,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 17:29 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 9,083 | $13.86 | $125,890.38 |
DisclosureSEC source: 0001209191-18-021781 · doc4.xml · nonDerivative · entry 2 Carey Robert · CIK 0001602064 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,106 Read SEC document |
| March 23, 2018 Filed Mar 27, 2018 17:29 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 31,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-021781 · doc4.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,189 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 13:50 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units · Derivative | 31,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-017613 · doc4.xml · derivative · entry 4 Carey Robert · CIK 0001602064 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 31,025 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: On March 5, 2014, the reporting person was granted 124,100 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On March 5, 2014, the reporting person was granted 124,100 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 13:50 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 13,836 | $15.83 | $219,023.88 |
DisclosureSEC source: 0001209191-18-017613 · doc4.xml · nonDerivative · entry 2 Carey Robert · CIK 0001602064 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,189 Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 13:50 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 31,025 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-017613 · doc4.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,025 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| June 05, 2017 Filed Jun 7, 2017 22:04 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001140361-17-024397 · doc1.xml · derivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-06-04 F1 · derivative.exercise_date: Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon the cessation of the Reporting Person's service on the Board of Directors of the Issuer. The shares subject to each option vest in monthly installments upon completion of each month of Board service over a one year period. Read SEC document |
| March 23, 2017 Filed Mar 24, 2017 18:28 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units · Derivative | 31,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-022835 · doc4.xml · derivative · entry 4 Carey Robert · CIK 0001602064 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,000 Underlying: Ordinary Shares · 31,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: On March 23, 2015, the reporting person was granted 124,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F2 · derivative.expiration_date: On March 23, 2015, the reporting person was granted 124,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| March 23, 2017 Filed Mar 24, 2017 18:28 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 14,167 | $14.56 | $206,271.52 |
DisclosureSEC source: 0001209191-17-022835 · doc4.xml · nonDerivative · entry 2 Carey Robert · CIK 0001602064 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,190 Read SEC document |
| March 23, 2017 Filed Mar 24, 2017 18:28 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 31,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-022835 · doc4.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| March 05, 2017 Filed Mar 7, 2017 16:55 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units · Derivative | 31,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-018785 · doc4.xml · derivative · entry 4 Carey Robert · CIK 0001602064 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,025 Underlying: Ordinary Shares · 31,025 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: On March 5, 2014, the reporting person was granted 124,100 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F2 · derivative.expiration_date: On March 5, 2014, the reporting person was granted 124,100 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| March 05, 2017 Filed Mar 7, 2017 16:55 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 14,268 | $16.11 | $229,857.48 |
DisclosureSEC source: 0001209191-17-018785 · doc4.xml · nonDerivative · entry 2 Carey Robert · CIK 0001602064 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,357 Read SEC document |
| March 05, 2017 Filed Mar 7, 2017 16:55 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 31,025 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-018785 · doc4.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 18:40 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 30,000 | $16.00 | $480,000.00 |
DisclosureSEC source: 0001209191-17-016933 · doc4.xml · nonDerivative · entry 3 Carey Robert · CIK 0001602064 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Robert F. Carey III Trust dated 4/24/2001 Disclosed balance after: 95,408 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 18:40 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | OtherWarrant to Purchase Ordinary Shares (Right to Buy) · Derivative | 6,913 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-17-016933 · doc4.xml · derivative · entry 5 Carey Robert · CIK 0001602064 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Robert F. Carey III Trust dated 4/24/2001 Disclosed balance after: 0 Underlying: Ordinary Shares · 6,913 shares Expires 2017-03-02 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 18:40 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | SaleOrdinary Shares | 1,808 | $16.48 | $29,795.84 |
DisclosureSEC source: 0001209191-17-016933 · doc4.xml · nonDerivative · entry 2 Carey Robert · CIK 0001602064 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Robert F. Carey III Trust dated 4/24/2001 Disclosed balance after: 125,408 F2 · kind: Exercise of a warrant to purchase 6,913 ordinary shares of the Issuer for $4.308 per share. The reporting person paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 1,808 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 5,105 shares. The warrant was scheduled to expire on March 2, 2017. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 18:40 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | OtherOrdinary Shares | 6,913 | $4.31 | $29,781.20 |
DisclosureSEC source: 0001209191-17-016933 · doc4.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Robert F. Carey III Trust dated 4/24/2001 Disclosed balance after: 127,216 F1 · balance_after: Includes 38,242 shares which were transferred from the Reporting Person to the Trust on January 11, 2017. Read SEC document |
| January 19, 2017 Filed Jan 20, 2017 13:03 UTC | ARGOS THERAPEUTICS INC ARGS · Entity 167312 | GrantStock Option (right to buy) · Derivative | 9,500 | $0.00 Strike: $4.85 | $0.00 |
DisclosureSEC source: 0001602064-17-000002 · primary_doc.xml · derivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock · 9,500 shares Expires 2027-01-18 Read SEC document |
| December 31, 2016 Filed Jan 4, 2017 11:41 UTC | ARGOS THERAPEUTICS INC ARGS · Entity 167312 | GrantCommon Stock | 2,351 | $0.00 | $0.00 |
DisclosureSEC source: 0001602064-17-000001 · primary_doc.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,206 F1 · shares: The reporting person has received a fully vested stock award for shares of the Company's common stock. For calendar year 2016, the Company has elected to make common stock awards in lieu of cash payments of director fees otherwise payable under the director compensation policy. The number of shares of common stock awarded represent the quotient of (A) such director fees divided by (B) the Company's closing stock price on the date awarded, rounded down to the nearest whole share of common stock. Read SEC document |
| September 30, 2016 Filed Oct 3, 2016 13:31 UTC | ARGOS THERAPEUTICS INC ARGS · Entity 167312 | GrantCommon Stock | 2,263 | $0.00 | $0.00 |
DisclosureSEC source: 0001602064-16-000006 · primary_doc.xml · nonDerivative · entry 1 Carey Robert · CIK 0001602064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,855 F1 · shares: The reporting person has received a fully vested stock award for shares of the Company's common stock. For calendar year 2016, the Company has elected to make common stock awards in lieu of cash payments of director fees otherwise payable under the director compensation policy. The number of shares of common stock awarded represent the quotient of (A) such director fees divided by (B) the Company's closing stock price on the date awarded, rounded down to the nearest whole share of common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.